Positive results with new oral microbiome drug for C. diff

Finch Therapeutics announced positive topline results from a randomized controlled trial of CP101 for the prevention of recurrent Clostridioides difficile infection, according to a press release.In PRISM3, a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, researchers assessed the investigational oral microbiome drug CP101 in 206 patients with recurrent C. difficile at 51 sites across the United States and Canada.“It is really exciting and will change the microbiome field going forward,” Jessica Allegretti, MD, MPH, principal investigator in the PRISM3Read More

Share on facebook
Share on twitter
Share on linkedin